ROCKVILLE, Md., Nov. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it will host an Analyst and Investor Day in New York City on Tuesday, November 22, 2005 from 12:00 - 2:00 p.m. The meeting will focus on HIF-1: A Key Target in Multiple Mechanism Cancer Therapeutics.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Gregg L. Semenza, M.D., Ph.D., will serve as keynote speaker for the event. Dr. Semenza is a Professor in the Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, and Institute of Genetic Medicine at the Johns Hopkins University, and a recognized world authority on oxygen homeostasis and cellular responses to oxygen deprivation. Presentations will also be given by Theresa M. LaVallee, Ph.D., Senior Director of Cell Biology and James S. Burns, President and CEO of EntreMed.
“We are honored that Dr. Semenza will lead this informative session covering an important emerging area for cancer therapy. HIF-1alpha, a key regulator of tumor angiogenesis, is over-expressed in more than 70% of human tumors. HIF-1alpha over-expression correlates with tumor aggressiveness, metastases and poor prognosis,” commented James S. Burns.
Mr. Burns continued, “Our lead clinical-stage drug candidate, Panzem(R) (2ME2), and our novel tubulin binding agent, ENMD-1198, are both inhibitors of HIF-1alpha. HIF-1alpha’s down-regulation is closely associated with the tubulin inhibitor properties of both compounds. EntreMed’s product candidates are part of a next generation of multi-mechanism drugs that attack disease cells directly and the blood vessels that nourish them.”
Live presentations and a question and answer session following the presentations will be web cast. The event can be accessed through the Company’s web site at http://www.entremed.com. An archived version of the presentation, including the presentation slides, will be available in the same location for 90 days. For more information on the event, please contact Jane Petrino, 212-845-4274 or jane.petrino@eurorscg.com.
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations of EntreMed, Inc., +1-240-864-2643.
Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comEntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com//
